The California-based biotech continued its rocket-like ascent in 2015–just two years ago it ranked No. 250 on the 500–due to booming sales of its breakthrough Hepatitis C medications. Those drugs–Sovaldi and Harvoni–which cost a fortune, but also cure a chronic, devastating disease, sparked a national debate on drug pricing. They also drove Gilead’s bottom and top lines in 2015–revenues and profits jumped 31% and 50%, respectively. John Milligan, Gilead’s new CEO faces rockier road in 2016: the competition is stiffer and IP challenges and pricing pressures loom.
News about Gilead Sciences
If he pulls it off, he will make more than all of his peers combined.
Overall deal value declined last year.
The biotech giant can now speed up the drug review process.
These tech and pharma companies could cash in on "repatriation."
It's to protect the company's best-selling drug.